Table 3

Predictors of treatment success for MDR, 2006–2015

OR (95% CI)P valuesAdjusted OR (95% CI)P values
Treatment group
 Hospitalised1.01.0
 Community1.09 (0.70 to 1.68)0.711.0 (0.63 to 1.60)0.99
Sex
 Female1.01.0
 Male0.80 (0.51 to 1.27)0.350.67 (0.41 to 1.09)0.11
Age
 <441.01.0
 ≥440.53 (0.34 to 0.83)0.0060.40 (0.24 to 0.67)<0.001
Resistance pattern
 INH+RIF or GXP/RIF1.01.0
 INH+RIF+1.20 (0.78 to 1.85)0.411.15 (0.73 to 1.83)0.54
 XDR0.31 (0.04 to 2.27)0.250.28 (0.04 to 2.23)0.23
HIV
 Negative1.01.0
 Positive0.47 (0.29 to 0.78)0.0030.33 (0.19 to 0.64)<0.001
Baseline BMI
 ≥161.01.0
 <160.41 (0.26 to 0.64)<0.0010.40 (0.25 to 0.64)<0.001
  • BMI, body mass index; GXP, GeneXpert MTB/RIF; INH, isoniazid; INH+RIF+, additional drug resistance beyond INH and RIF, not XDR; MDR, multidrug resistant; RIF, rifampicin; XDR, extensively drug-resistant TB.